Navigation Links
CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
Date:2/19/2008

Company's Proprietary Technology Adopted in 16% of U.S. Cardiology Offices

and Underscores Growing ICG Acceptance and Clinical Importance

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's BioZ ICG technology is featured in American College of Cardiology's ACCEL audio series.

ACCEL is the American College of Cardiology's monthly audio series distributed to thousands of cardiologists with the latest cardiovascular news on diagnosis, treatment, and research. This is the first time that ICG has been the subject of an ACCEL interview. Dr. John Schroeder, Professor of Medicine, Stanford University School of Medicine, Stanford, California, is interviewed by the editor of ACCEL, Dr. Richard Conti and discusses ICG technology, validity, and a number of clinical studies which highlight ICG's clinical utility in high blood pressure shortness of breath and heart failure patients.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are extremely pleased that the American College of Cardiology would elect to highlight ICG on its ACCEL monthly audio series and believe it validates the widespread use of our technology in cardiology offices and its importance in the care of cardiac patients. The interview is very favorable in our judgment, and we hope it will help further increase awareness of ICG among cardiologists."

BioZ ICG technology is available in approximately one out of every six (16%) of cardiology offices as well as one out of every five (20%) outpatient heart failure clinics in the United States. Over one million patient applications are performed annually.

John Schroeder, M.D., F.A.C.C., Professor of Medicine, Stanford University School of Medicine, Stanford, California, stated, "As a clinician at an academic institution, I was pleased to be interviewed on impedance cardiography and to share insights into this important, innovative cardiac technology that assists clinicians in the care of heart failure, shortness of breath and high blood pressure patients. Since heart failure admissions continue to increase in the United States, as well as overall cardiac healthcare for the elderly, this important advancement in technology which allows outpatient assessment is a welcome addition to the practicing physician. If we can provide enhanced data and care for these patients in physician offices, it can help reduce costly emergency care visits and hospitalizations."

For further information on the interview, please contact Marjorie Swingle at mswingle@cdic.com.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2006 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
3. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. Novel Technology Breaks Through Cancer Pain
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Advanced Cell Technology Announces Proposed Financing
8. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an ... treatment of Alzheimer’s disease, announced today it has been selected to present at the ... Breakers in Palm Beach, Florida. The purpose of the Forum is to help ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
Breaking Biology News(10 mins):